Effect of Phenobarbital on Elevated Direct Bilirubin Concentrations in Neonates and Infants in the Neonatal Intensive Care Unit.

OBJECTIVE Few studies have evaluated the effect of phenobarbital (PB) on elevated direct bilirubin (DB) plasma concentrations in neonates and infants, and none have compared its effect with a control group with matched study baseline DB values. The purpose of this study was to quantify changes in elevated DB plasma concentrations (≥2 mg/dL) in neonates and infants between a PB-treated and control group. METHODS A retrospective, observational, matched, cohort study was performed comparing patients between a PB-treated group and a control group with similar study baseline plasma DB values ≥2 mg/dL over an 8-week period. The percent change in DB plasma concentrations from study baseline was compared for each week of the study period. RESULTS During the 8-year study period, 310 patients had DB plasma concentrations ≥2 mg/dL, of which 26 remained in each group after exclusions. The PB group had increased DB concentrations and the control group had decreased DB concentrations when compared with their study baseline DB concentrations each week of the study period. By study end, the mean DB concentration increased by 11.2% in the PB group and decreased by 48.5% in the control group (p = 0.02). In multiple regression analysis, only birth weight (standardized coefficient = 0.44, p = 0.02), and gastrointestinal obstruction (standardized coefficient = -0.4, p = 0.03) were associated with significant percent change in DB concentrations. CONCLUSIONS This study demonstrated PB does not improve cholestasis in neonates and infants.

[1]  A. Sherman,et al.  Ursodeoxycholic acid versus phenobarbital for cholestasis in the Neonatal Intensive Care Unit , 2018, BMC Pediatrics.

[2]  N. Hadžić,et al.  Guideline for the Evaluation of Cholestatic Jaundice in Infants: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition , 2017, Journal of pediatric gastroenterology and nutrition.

[3]  P. Forcelli,et al.  Anticonvulsant drug–induced cell death in the developing white matter of the rodent brain , 2016, Epilepsia.

[4]  P. Forcelli,et al.  Brief postnatal exposure to phenobarbital impairs passive avoidance learning and sensorimotor gating in rats , 2014, Epilepsy & Behavior.

[5]  A. Bavdekar,et al.  Management of neonatal cholestasis: Consensus statement of the pediatric gastroenterology chapter of Indian academy of pediatrics , 2014, Indian Pediatrics.

[6]  M. Thibault,et al.  Parenteral nutrition-associated liver disease: a retrospective study of ursodeoxycholic Acid use in neonates. , 2014, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG.

[7]  A. Stark,et al.  Adverse neurodevelopmental outcomes after exposure to phenobarbital and levetiracetam for the treatment of neonatal seizures , 2013, Journal of Perinatology.

[8]  Amy G Feldman,et al.  Neonatal Cholestasis. , 2013, NeoReviews.

[9]  P. Tsao,et al.  Ursodeoxycholic acid (UDCA) therapy in very-low-birth-weight infants with parenteral nutrition-associated cholestasis. , 2004, The Journal of pediatrics.

[10]  J. Olney,et al.  Antiepileptic drugs and apoptotic neurodegeneration in the developing brain , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[11]  A. Green,et al.  γ-Glutamyltransferase: value of its measurement in paediatrics , 2002, Annals of clinical biochemistry.

[12]  D. Hirtz,et al.  Late Cognitive Effects of Early Treatment with Phenobarbital , 1999, Clinical pediatrics.

[13]  J. Thorp,et al.  Does perinatal phenobarbital exposure affect developmental outcome at age 2? , 1999, American journal of perinatology.

[14]  R. Shamir,et al.  Parenteral Nutrition-Associated Cholestasis in Preterm Neonates: Evaluation of Ursodeoxycholic Acid Treatment , 1999, Journal of pediatric endocrinology & metabolism : JPEM.

[15]  D. Rubin,et al.  In utero exposure to phenobarbital and intelligence deficits in adult men. , 1995, JAMA.

[16]  B. Strandvik,et al.  Phenobarbital Can Aggravate a Cholestatic Bile Acid Pattern in Infants with Obstructive Cholangiopathy , 1990, Journal of pediatric gastroenterology and nutrition.

[17]  M. South,et al.  Parenteral nutrition-associated cholestasis: recovery following phenobarbitone. , 1987, JPEN. Journal of parenteral and enteral nutrition.

[18]  R. Merritt,et al.  Phenobarbital does not prevent total parenteral nutrition-associated cholestasis in noninfected neonates. , 1986, JPEN. Journal of parenteral and enteral nutrition.

[19]  J. Boyer,et al.  Phenobarbital Effects in Cholestatic Liver Disease , 1975 .

[20]  S. Robinson,et al.  Bilirubin excretion in rats with normal and impaired bilirubin conjugation: effect of phenobarbital. , 1971, The Journal of clinical investigation.

[21]  C. Klaassen Effects of phenobarbital on the plasma disappearance and biliary excretion of drugs in rats. , 1970, The Journal of pharmacology and experimental therapeutics.

[22]  E. R. Peters,et al.  Phenobarbitone in cholestasis. , 1968, Lancet.

[23]  F. Suchy,et al.  Medical and Nutritional Management of Cholestasis in Infants and Children , 2022, Liver Disease in Children.